$SHPH

HRT FINANCIAL LP sold $373K of SHPH

HRT FINANCIAL LP sold 83,149 shares of Shuttle Pharmaceuticals Holdings, Inc. (SHPH) at an average of $4.48 ($4.48–$4.67, $0.37M total) across 2 trades over 2026-07-13 to 2026-07-14.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jul 15, 2026, 7:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 7:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SHPH
Neutral
medium confidence
Mentioned
$SHPH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SHPHNeutralLow
01

Why it matters

A 10% owner sold shares over two days at $4.48 to $4.67, reducing holdings to zero. This can modestly affect sentiment but does not introduce new operational or regulatory information.

02

Market read

Traders may monitor for follow-on selling or changes in insider ownership, but the disclosure alone is unlikely to drive a durable repricing.

03

What to watch

The filing does not confirm whether the sale was part of a 10b5-1 plan (it says no), so traders may overinterpret intent without additional context like prior filings or subsequent transactions.

Relevance 4/10Novelty 4/10Timing: Filed on 2026-07-15, covering sales dated 2026-07-13 to 2026-07-14.

Background

The article is an SEC Form 4 insider transaction disclosure for Shuttle Pharmaceuticals Holdings, Inc.

Company-level read

Ticker impact

$SHPHNeutralMedium confidence
Context

HRT Financial LP, a 10% owner, sold 83,149 Shuttle Pharmaceuticals shares in open-market trades for about $372.7K, leaving 0 shares.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and should fade unless follow-on selling appears.

Evidence & confidence

Form 4 shows the transaction details and post-sale holdings, but provides no new company-specific operating or regulatory catalyst.

Market effects

No clear sector read-through from a single disclosed insider sale without accompanying company news.

None indicated.

None indicated.

Counterpoint

The holder may be rebalancing or meeting liquidity needs; insider sales are common and do not necessarily signal deteriorating fundamentals.

Key entities

  • Shuttle Pharmaceuticals Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • HRT Financial LP

    10% owner who executed the open-market sale.

Related articles